AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7977146 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk chocolate bar (46 g)
Number of subjects: 42
Study 7977146 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate snack
Number of subjects: 42
Study 2593864 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate 1 mg (Group A)
Number of subjects: 60
Study 2593864 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate 0.5 mg (Group B)
Number of subjects: 60
Study 2593864 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 5 mg (Group C)
Number of subjects: 60
Study 2593864 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 2.5 mg (Group D)
Number of subjects: 60
Study 2593864 — intervention group
Group type: EXPERIMENTAL
Intervention: High progestogen doses (Norethisterone acetate 1 mg and Megestrol acetate 5 mg)
Number of subjects: 60
Study 2593864 — intervention group
Group type: EXPERIMENTAL
Intervention: High progestogen doses (Norethisterone acetate 1 mg and Megestrol acetate 5 mg) with women under 67 kg or last menstruation over 5 years ago
Number of subjects: 60
Study 30192327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous furosemide plus enhanced recovery after surgery on postoperative day 1 and 2
Number of subjects: 123
Study 30192327 — intervention group
Group type: COMPARATOR
Intervention: Enhanced recovery after surgery alone
Number of subjects: 123
Study 26833820 — intervention group
Group type: EXPERIMENTAL
Intervention: ERSPC-RC
Number of subjects: 2001
Study 26833820 — intervention group
Group type: EXPERIMENTAL
Intervention: ERSPC-PHI
Number of subjects: 2001
Study 26833820 — intervention group
Group type: COMPARATOR
Intervention: PCPT-RC
Number of subjects: 2001
Study 26833820 — intervention group
Group type: COMPARATOR
Intervention: ERSPC-RC vs PCPT-RC
Number of subjects: 2001
Study 26833820 — intervention group
Group type: COMPARATOR
Intervention: ERSPC-RC vs ERSPC-PHI
Number of subjects: 2001
Study 24513589 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of Chronic Care Model (CCM) elements via a specially trained practice nurse
Number of subjects: 326
Study 24513589 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 326
Study 22122753 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief face‐to‐face health promotion intervention with a 'pledge' using brief negotiation techniques
Number of subjects: 128
Study 22122753 — intervention group
Group type: COMPARATOR
Intervention: Standard advice‐giving techniques (Control)
Number of subjects: 128
Study 20795385 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumo 23 vaccine
Number of subjects: 45
Study 20795385 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 45
Study 19025058 — intervention group
Group type: EXPERIMENTAL
Intervention: Aniracetam (400 mg, 2 x 200 mg/capsule)
Number of subjects: 20
Study 19025058 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of Aniracetam (400 mg)
Number of subjects: 20
Study 15083988 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist counseling (three levels)
Number of subjects: 0
Study 11473680 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (active treatment)
Number of subjects: 15
Study 11473680 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 15
Study 10028858 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha (rIFN-alpha) alone (1.5 million units/m2 body surface, 3 times a week for 24 weeks)
Number of subjects: 29
Study 10028858 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone (2.2 mg/kg/day for 3 weeks, tapered within 1 week) followed by rIFN-alpha (same dose as above)
Number of subjects: 29
Study 8015423 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (vasoactive drug) administered postoperatively
Number of subjects: 0
Study 8015423 — intervention group
Group type: COMPARATOR
Intervention: Placebo (untreated patients)
Number of subjects: 0
Study 2778114 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied corticosteroid formulations of different potencies
Number of subjects: 0
Study 2778114 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicles
Number of subjects: 0
Study 31573086 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive intraoperative peritoneal lavage (EIPL)
Number of subjects: 295
Study 31573086 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (no EIPL)
Number of subjects: 295
Study 28279542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg/kg via intravenous piggyback over 15 min
Number of subjects: 60
Study 28279542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25080450 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 20 mg
Number of subjects: 395
Study 25080450 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg
Number of subjects: 395
Study 25080450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 25080450 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 20 mg (Genotype 4)
Number of subjects: 395
Study 25080450 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg (Genotype 4)
Number of subjects: 395
Study 25080450 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Genotype 4)
Number of subjects: 395
Study 23904676 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 30
Study 23904676 — intervention group
Group type: EXPERIMENTAL
Intervention: Servoventilation
Number of subjects: 30
Study 23904676 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 30
Study 21200078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 216
Study 21200078 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 216
Study 19826270 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation guided by hourly urine output
Number of subjects: 16
Study 19826270 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation guided by intrathoracic blood volume index
Number of subjects: 16
Study 16477215 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole and caspofungin
Number of subjects: 40
Study 16477215 — intervention group
Group type: COMPARATOR
Intervention: Lipid formulation of AmB (Control)
Number of subjects: 40
Study 15465432 — intervention group
Group type: EXPERIMENTAL
Intervention: Low beta training (12-15 Hz)
Number of subjects: 0
Study 15465432 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha/theta training (8-11 Hz/5-8 Hz)
Number of subjects: 0
Study 15465432 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta1 training (15-18 Hz)
Number of subjects: 0
Study 10796750 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal Baclofen
Number of subjects: 132
Study 10796750 — intervention group
Group type: COMPARATOR
Intervention: Tizanidine
Number of subjects: 132
Study 10796750 — intervention group
Group type: EXPERIMENTAL
Intervention: Other drugs (Gabapentine, Clonidine, Diazepam, Amytal, oral Baclofen)
Number of subjects: 132
Study 9288368 — intervention group
Group type: EXPERIMENTAL
Intervention: Toki‐shakuyaku‐san (TSS)
Number of subjects: 0
Study 9288368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8309899 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical chorionic villus sampling (CVS)
Number of subjects: 800
Study 8309899 — intervention group
Group type: COMPARATOR
Intervention: Amniocentesis (AC)
Number of subjects: 800
Study 2873015 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-treated group (hydrochlorothiazide, propranolol, methyldopa)
Number of subjects: 785
Study 2873015 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 785
Study 2873015 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-treated group
Number of subjects: 785
Study 2873015 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 785
Study 29626416 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of 16 mU/min (Group I)
Number of subjects: 900
Study 29626416 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mU/min (Group II)
Number of subjects: 900
Study 29626416 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mU/min (Group III)
Number of subjects: 900
Study 29626416 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mU/min quarter‐hourly (Group IV)
Number of subjects: 900
Study 29626416 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe pump (Group V)
Number of subjects: 900
Study 25862769 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 31
Study 25862769 — intervention group
Group type: COMPARATOR
Intervention: Control group (general rehabilitation exercise)
Number of subjects: 31
Study 25226604 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-training group
Number of subjects: 44
Study 25226604 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group
Number of subjects: 44
Study 22401642 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine 3 mg/24 hours via transdermal patch
Number of subjects: 0
Study 22401642 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine 8 mg/24 hours via transdermal patch
Number of subjects: 0
Study 22401642 — intervention group
Group type: COMPARATOR
Intervention: Single large patch vs. 2 smaller patches
Number of subjects: 0
Study 22401642 — intervention group
Group type: COMPARATOR
Intervention: Patch application sites (hip, shoulder, abdomen, flank, thigh, upper arm)
Number of subjects: 0
Study 20412640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection
Number of subjects: 695
Study 17333332 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored decision aid (DA)
Number of subjects: 145
Study 17333332 — intervention group
Group type: COMPARATOR
Intervention: Control pamphlet
Number of subjects: 145
Study 15592189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m N-NOET
Number of subjects: 50
Study 15592189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m N-NOET with reinjection protocol
Number of subjects: 50
Study 15592189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m N-NOET stress imaging
Number of subjects: 50
Study 15592189 — intervention group
Group type: COMPARATOR
Intervention: Tl-201
Number of subjects: 50
Study 11930708 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary expansion and protraction therapy
Number of subjects: 40
Study 11930708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no orthodontic treatment)
Number of subjects: 40
Study 9218016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate (Elmiron)
Number of subjects: 398
Study 9218016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study 8389104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 0
Study 8389104 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 0
Study 8389104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8389104 — intervention group
Group type: COMPARATOR
Intervention: Control day (no allergen)
Number of subjects: 0
Study 2874085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (3 doses of 0.5 g)
Number of subjects: 159
Study 2874085 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin (3 doses of 1 g)
Number of subjects: 159
Study 2874085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 31055949 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook advertising
Number of subjects: 302
Study 31055949 — intervention group
Group type: COMPARATOR
Intervention: Mailing recruitment letters
Number of subjects: 302
Study 27859893 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin camouflage program (4 sessions)
Number of subjects: 66
Study 27859893 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 66
Study 28690353 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional cash transfer (Child Grant)
Number of subjects: 0
Study 25509057 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES)
Number of subjects: 20
Study 25509057 — intervention group
Group type: COMPARATOR
Intervention: Sham ES (placebo)
Number of subjects: 20
Study 22166848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (systolic blood pressure < 120 mm Hg)
Number of subjects: 4733
Study 22166848 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (systolic blood pressure < 140 mm Hg)
Number of subjects: 4733
Study 22166848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (HbA1c < 0.060)
Number of subjects: 4733
Study 22166848 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control (HbA1c 0.070‐0.079)
Number of subjects: 4733
Study 22166848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 4733
Study 22166848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 4733
Study 22166848 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intensive treatment of glycemia and blood pressure
Number of subjects: 4733
Study 19384953 — intervention group
Group type: EXPERIMENTAL
Intervention: TYR Arg402Gln variant
Number of subjects: 1673
Study 19384953 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC45A2 Phe374Leu variant
Number of subjects: 1673
Study 19384953 — intervention group
Group type: EXPERIMENTAL
Intervention: TYRP1 rs1408799
Number of subjects: 1673
Study 19384953 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC45A2 1721 C>G
Number of subjects: 1673
Study 19384953 — intervention group
Group type: EXPERIMENTAL
Intervention: TYR Ser192Tyr
Number of subjects: 1673
Study 19384953 — intervention group
Group type: EXPERIMENTAL
Intervention: TYR haplotype carrying only the Arg402Gln variant allele
Number of subjects: 1673
Study 19384953 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA2 Arg419Gln
Number of subjects: 1673
Study 19384953 — intervention group
Group type: EXPERIMENTAL
Intervention: ASIP g.8818 A>G
Number of subjects: 1673
Study 19384953 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype near ASIP (rs4911414[T] and rs1015362[G])
Number of subjects: 1673
Study 17465473 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butyl bromide injection
Number of subjects: 200
Study 17465473 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 200
Study 15318679 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail survey delivery
Number of subjects: 0
Study 15318679 — intervention group
Group type: COMPARATOR
Intervention: Post survey delivery (with e-mail access)
Number of subjects: 0
Study 15318679 — intervention group
Group type: COMPARATOR
Intervention: Post survey delivery (without e-mail access)
Number of subjects: 0
Study 11094012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg rocuronium (adults)
Number of subjects: 72
Study 11094012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 mg/kg rocuronium (children)
Number of subjects: 72
Study 11094012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12, 0.18, or 0.24 mg/kg rocuronium (children)
Number of subjects: 72
Study 11094012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06, 0.12, or 0.18 mg/kg rocuronium (adults)
Number of subjects: 72
Study 9067498 — intervention group
Group type: EXPERIMENTAL
Intervention: BMSC
Number of subjects: 82
Study 8354583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg daily for 7 days
Number of subjects: 51
Study 3720527 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and d-amphetamine combination
Number of subjects: 10
Study 3720527 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 10
Study 3720527 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine alone
Number of subjects: 10
Study 30024233 — intervention group
Group type: EXPERIMENTAL
Intervention: Infographic letter
Number of subjects: 3
Study 30024233 — intervention group
Group type: COMPARATOR
Intervention: Control letter
Number of subjects: 3
Study 28065453 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 56
Study 28065453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 26239594 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly supervised exercise programme (6 weeks supervised, followed by 6 weeks self-administered)
Number of subjects: 51
Study 26239594 — intervention group
Group type: COMPARATOR
Intervention: Self-administered exercise programme (12 weeks)
Number of subjects: 51
Study 23325435 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended antibacterial prophylaxis for 48 hours or until thoracostomy tubes were removed (n = 125)
Number of subjects: 251
Study 23325435 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 126)
Number of subjects: 251
Study 23325435 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended antibacterial prophylaxis
Number of subjects: 251
Study 23325435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 21601826 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cefazolin
Number of subjects: 404
Study 21601826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 18513146 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 2
Study 18513146 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir plus ritonavir
Number of subjects: 2
Study 18513146 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir
Number of subjects: 2
Study 16542127 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted, tailored self-management intervention
Number of subjects: 335
Study 16542127 — intervention group
Group type: COMPARATOR
Intervention: Health risk appraisal with feedback control
Number of subjects: 335
Study 12657224 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine infusion (5mg in 5min) during head-up tilt test (Clom-HUT)
Number of subjects: 126
Study 12657224 — intervention group
Group type: COMPARATOR
Intervention: Conventional head-up tilt test (Con-HUT)
Number of subjects: 126
Study 12657224 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine infusion during tilt test
Number of subjects: 126
Study 10722899 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of a single low pH orange drink for 15 days, 2 times per day
Number of subjects: 16
Study 10722899 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of a single low pH orange drink for 15 days, 4 times per day
Number of subjects: 16
Study 10722899 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing frequency of consumption (2 vs 4 drinks per day)
Number of subjects: 16
Study 10722899 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of a single low pH orange drink for 15 days
Number of subjects: 16
Study 9193243 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose indomethacin sodium for the prevention of intraventricular hemorrhage
Number of subjects: 381
Study 9193243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial ultrasonographic (US) scan
Number of subjects: 381
Study 9193243 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchopulmonary dysplasia and abnormal cranial US scan
Number of subjects: 381
Study 9193243 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorioamnionitis, treatment with surfactant, bronchopulmonary dysplasia, abnormal cranial US findings
Number of subjects: 381
Study 9193243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial US findings (grade 3 to 4 intraventricular hemorrhage, periventricular leukomalacia, ventriculomegaly)
Number of subjects: 381
Study 1586272 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-range lithium levels (0.8 to 1.0 mmol/L)
Number of subjects: 94
Study 1586272 — intervention group
Group type: COMPARATOR
Intervention: Low-range lithium levels (0.4 to 0.6 mmol/L)
Number of subjects: 94
Study 1586272 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-range lithium therapy
Number of subjects: 94
Study 1586272 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset of hypomanic symptoms
Number of subjects: 94
Study 1586272 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypomanic symptoms
Number of subjects: 94
Study 1586272 — intervention group
Group type: COMPARATOR
Intervention: Subclinically depressed symptoms
Number of subjects: 94
Study 31779715 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min cycling (EX)
Number of subjects: 14
Study 31779715 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min cycling with dietary energy replacement (EX + R)
Number of subjects: 14
Study 31779715 — intervention group
Group type: COMPARATOR
Intervention: Rest control (CON)
Number of subjects: 14
Study 31098961 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine infusion (5 mg·kg−1)
Number of subjects: 34
Study 31098961 — intervention group
Group type: COMPARATOR
Intervention: Active placebo infusion (diphenhydramine 50 mg)
Number of subjects: 34
Study 28931031 — intervention group
Group type: EXPERIMENTAL
Intervention: Scientific reframing intervention
Number of subjects: 154
Study 28931031 — intervention group
Group type: COMPARATOR
Intervention: Traditional informed consent procedure (control)
Number of subjects: 154
Study 27107066 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion RSB analgesia
Number of subjects: 46
Study 27107066 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-dose RSB analgesia
Number of subjects: 46
Study 27107066 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 46
Study 27107066 — intervention group
Group type: EXPERIMENTAL
Intervention: All RSB groups (single-dose, repeated-dose, continuous infusion)
Number of subjects: 46
Study 27107066 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (benign and cancer)
Number of subjects: 46
Study 25060946 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/amlodipine 20/5 mg
Number of subjects: 0
Study 25060946 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 40 mg
Number of subjects: 0
Study 25060946 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 0